INS and obesity disorder: Because the pathogenesis of obesity-related metabolic dysfunction is multifactorial and complex, diverse strategies have been employed to hinder its development and manifestations, namely stimulating insulin production in pancreatic beta-cells, inhibiting hepatic glucose output, reducing glucose reabsorption in the kidney, and enhancing peripheral glucose uptake and insulin sensitivity (1).